The Insulin Signaling Pathway

By Laura Norton, PhD

Table of Contents

Insulin

Insulin is a peptide hormone that predominantly functions to reduce blood glucose levels. It is secreted from beta cells found in the islets of the pancreas in response to nutrient uptake and increased blood glucose levels. When insulin binds to its receptors on target cells, such as skeletal muscle cells and adipocytes, a signaling cascade is initiated, which culminates in the translocation of the glucose transporter GLUT4 from intracellular vesicles to the cell membrane. Once GLUT4 is incorporated into the plasma membrane, it functions to promote the uptake of extracellular glucose, which is then stored as glycogen in these cells, thereby regulating blood glucose [1].

Insulin also regulates blood sugar through inhibiting gluconeogenesis (de novo glucose production) and glycogenolysis (glycogen breakdown) in the liver. Besides regulating blood glucose levels, insulin also plays critical roles in facilitating protein and lipid synthesis and preventing the conversion of protein and fat to glucose.

While insulin is widely viewed as a glucose homeostasis regulating hormone, an increasing body of research is illuminating broader roles for this peptide. Insulin signaling pathways are highly conserved, with insulin-like signaling systems found in all metazoans, and they have been shown to regulate many evolutionarily conserved processes, including lifespan and reproduction [2].

The Insulin Receptor

The insulin receptor belongs to the superfamily receptor tyrosine kinases (RTKs) [3,4] and is activated by insulin, as well as insulin-like growth factors (IGF1-2). It is a heterotetrametric protein consisting of two extracellular α subunits and two transmembrane β subunits, which are linked together by disulfide bonds. Most RTKs bind directly to signaling proteins. The insulin receptor, however, binds to phosphorylated residues on partner proteins, namely a family of large docking proteins known as the insulin receptor substrate family (IRS1-6) [5,6], as well as the adapter protein Shc (Src homology 2 domain containing) [7].

Insulin Receptor Pathways

When insulin binds to the extracellular α subunits of the insulin receptor, a conformational change is induced, which then results in the autophosphorylation of several tyrosine residues present in the β subunits. These form the binding sites for IRS proteins, which contain phosphotyrosine (PTB) binding domains, or for Shc adapter proteins, containing src-homology 2 (SH2) domains. Binding of the insulin receptor to either IRS or Shc forms a platform that allows for the assembly of a signal transduction particle that gives rise to multiple intracellular signaling pathways [8].

Two principle pathways result from the insulin receptor-IRS interaction, the PI3K/AKT (also known as protein kinase B or PKB) pathway, and the Ras/MAPK (also known as extracellular signal regulated kinase or ERK). The PI3K (phosphoinositol 3-kinase) pathway is linked exclusively through IRS and is responsible for most of insulin's metabolic effects in the cell [9,10]. The MAPK pathway, on the other hand, stems from IRS, as well as Shc, and is involved in the regulation of gene expression and, in cooperation with the PI3K pathway, also regulates cell growth and differentiation [11].

PI3K / AKT Pathway

The PI3K pathway is activated by the binding of PI3K regulatory subunits p85 and p55 to IRS1 and IRS2. This results in the activation of the PI3K catalytic subunit, p110. Once the p110 subunit is activated, PI3K then catalyzes the phosphorylation of phosphatidylinositol (PI) to generate PIP3 (phosphatidylinositol 3,4,5-triphosphate) at the cell membrane [10,12]. PIP3 is an important second messenger that functions to recruit PDK1 (3-phosphoinositide dependent protein kinase-1) and AKT to the membrane, where phosphorylation of PDK1 then activates the serine/threonine residues of AKT [13]. From here, AKT plays a role in four critical downstream processes.

AKT is involved in the regulation of protein synthesis via the substrate protein mTOR, a serine/threonine kinase that functions as a nutrient sensor. mTOR stimulates protein synthesis through the phosphorylation of 4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1) and p70S6K (p70 ribosomal protein S6-kinase) [14].

AKT acts in the regulation of glycogen synthesis via glycogen synthase kinase 3 (GSK3), another serine/threonine kinase, which, amongst other roles, functions to inhibit glycogen synthase. GSK3 is inhibited when phosphorylated by AKT/PKB, which results in glycogen synthesis [15].

AKT plays a role in the regulation of gluconeogenic and adipogenic genes through the transcription factor FOXO1 (forkhead box-containing protein 1, subfamily O). In the absence of insulin, FOXO1 translocates to the nucleus where it activates the expression of genes involved in gluconeogenesis, such as phosphoenolpyruvate carboxykinase (PEPCK) [13]. It also activates the expression of cyclin G2, an atypical cyclin that blocks the cell cycle, which is inhibited by insulin [16], and appears to play a key role in insulin-induced mitogenesis. When phosphorylated by AKT, FOXO1 is sequestered in the cytoplasm, and therefore cannot activate the expression of its target genes.

Importantly, AKT also regulates translocation of the insulin-sensitive glucose transporter GLUT4, which is sequestered in intracellular vesicles of muscle cells and adipocytes to the cell membrane via exocytosis, where it facilitates the uptake of glucose from the blood into cells. This is achieved through the phosphorylation of AS160 (160-kDa AKT substrate), a GTPase-activating protein that activates RAB, a small G protein involved in membrane trafficking by blocking the exchange of GTP for GDP [17].

Figure 1: The PI3K and MAPK pathways.

PI3K and MAPK Pathway - Antibodies.com

Figure 2: The translocation of GLUT4 in the PI3K and MAPK pathways.

Translocation of GLUT4 in the PI3K and MAPK Pathways - Antibodies.com

Ras / MAPK Pathway

The MAPK pathway is an essential secondary branch of the insulin signaling pathway. It is activated independently of the PI3K pathway either through binding of growth factor receptor-bound protein 2 (Grb2) to tyrosine-phosphorylated Shc, or through Sh2 binding to the insulin receptor. The amino-terminal SH3 domain of Grb2 binds to proline-rich regions of proteins such as son-of-sevenless (SOS), a guanine nucleotide exchange factor that catalyzes the shift of membrane-bound Ras from an inactive form (Ras-GDP) to an active form (Ras-GTP) [18]. Activated Ras-GTP is then able to stimulate downstream effectors, such as the Serine/Threonine kinase Raf, which activates its downstream targets MEK1 and MEK2 that go on to phosphorylate and activate the MAP kinases Extracellular signal-regulated kinase 1/2 (ERK1/2). Activated ERK1/2 are directly involved in multiple cellular processes, ranging from cell proliferation and differentiation. They act by regulating gene expression as well as extra-nuclear events, such as cytoskeletal reorganization, through the phosphorylation and activation of target proteins in both the cytosol and nucleus [11].

Negative Regulation of Insulin Receptor Signaling and Signal Termination

Many mechanisms exist to attenuate, finetune, and terminate insulin signaling, both at the level of the receptor and at various points in the cascade. The insulin receptor and IRS proteins are negatively regulated by multiple systems, such as ligand-induced downregulation, tyrosine protein phosphatases, and serine phosphorylation. Phosphatases also regulate the subsequent steps in the associated protein kinase cascades.

Negative Feedback Loops in Response to Insulin

Negative feedback loops have been shown to play an essential role in finetuning this complex network [13,2]. Chronic exposure to insulin (hyperinsulinemia) results in a decrease of insulin receptors on the cell surface [19], as well as decreased IRS1 and IRS2 in vitro and in vivo in mice, which has been linked to insulin resistance in animal models [13]. The decrease in insulin receptors occurs through endocytosis by clathrin-coated vesicles. These receptors are then recycled or degraded within the lysosomes of the cell [20]. Receptor endocytosis has since been demonstrated to be a critical negative feedback mechanism that is relevant to the entire class of RTKs.

IRS signaling is negatively regulated by serine phosphorylation and kinases, such as ERK, S6 kinase, and c-Jun-N-terminal kinase (JNK), which are all activated by insulin. This is another negative feedback mechanism in the insulin signaling pathway [13]. The receptor for TNFα (TNFR), which predominantly functions in apoptosis and inflammation, induces IRS1 serine phosphorylation through JNK [13], causing insulin resistance in vitro, and in vivo in animal models as well as humans [21].

Attenuation of Insulin Signaling by Protein and Phospholipid Phosphatases

PTP1B is a major protein tyrosine phosphatase that dephosphorylates the insulin receptor. This protein resides in the endoplasmic reticulum and acts on the insulin receptor during internationalization and recycling of the receptor to the plasma membrane [22,23]. PTP1B also acts to dephosphorylate residues on activated IGF-1R and IRS proteins to reduce their activity. PTP1B knockout mice have been shown to be more sensitive to insulin and exhibit improved glucose tolerance [24,25].

The serine/threonine protein phosphatase 1 (PP1) is known to play a role in both glucose and lipid metabolism through the regulation of multiple rate-limiting enzymes, including glycogen synthase, hormone-sensitive lipase, or acetyl CoA carboxylase [26]. Protein phosphatase 2A (PP2A) also plays a critical role in regulating the activities of many protein kinases involved in the insulin cascade, including Akt, PKC, and ERK [27]. Interestingly, PP2A has been demonstrated to be hyperactivated in diabetic states [28].

Protein phosphatases 2B (PP2B), another serine/threonine phosphatase also known as calcineurin, has been shown to dephosphorylate Akt [29]. PH domain leucine-rich repeat protein phosphatases PHLPP-1 and PHLPP-2, members of the PP2C family, act to dephosphorylate both Akt and PKCs [30]. When PHLPP1 is over expressed in cells, the function of Akt and GSK3 activity is reduced. This results in a decrease in glycogen synthesis and glucose transport [31]. Obese and diabetic patients have been shown to have elevated levels of PHLPP1 in both adipose tissue and skeletal muscle which correlates with decreased Akt2 phosphorylation [31,32].

Negative regulation of the PI3K pathway occurs through dephosphorylation and subsequent inactivation of PIP3 by phospholipid phosphatases such as the tumor suppressor PTEN (phosphatase and tensin homolog) and SHIP2 (SH2-containing inositol 5'-phosphatase-2). PTEN dephosphorylates phosphoinositides on the 3'-position, whereas SHIP2 functions at the 5'-position [33].

Other Negative Modulators of Insulin Receptor Signaling

Suppressor of Cytokine Signaling (SOCS) proteins also function to attenuate insulin receptor signaling. These are mediators of cytokine receptor signaling, such as leptin and IL-6 receptors that act through Janus kinases (JAK) and signal transduction, as well as activation of transcription (STAT) proteins [34,35]. SOCS1, SOCS3, SOCS6, and SOCS7 act by binding to the insulin receptor to inhibit signaling, as well as by targeting IRS-1 and IRS-2 for proteasomal degradation [35].

Figure 3: Negative regulators of the insulin signaling pathway.

Negative Regulators of the Insulin Signaling Pathway - Antibodies.com

Dysregulated Insulin Signaling and Disease

Type 2 Diabetes

Type 2 diabetes is the primary disease associated with insulin and the insulin signaling pathways. This complex and heterogeneous disorder is caused by a combination of lifestyle and environmental factors, such as the typical western diet (which is high in fats and sugars), inactivity, and obesity, and is further modified by various genetic determinants [36]. Type 2 Diabetes is caused by two factors, insulin sensitivity (or insulin resistance) attributed to dysregulation of the insulin receptor signaling cascade, and changes in the production and secretion of insulin by the beta cells of the pancreas in response to elevated glucose. However, the relative impact of both defects on the development of diabetes has not yet been ascertained, nor have the specific molecular events at the tissue and cellular level [2]. As insulin receptors are present on many different cell types, dysregulation of the insulin signaling network effects multiple organs of the body in diabetes.

Thrombosis and Atherosclerosis

Heart attacks and strokes, precipitated by pathological blood clots (thrombi), are the leading cause of death in diabetic patients. The reason for this is twofold; firstly, patients with diabetes have an increased risk of developing more extensive atherosclerosis (AS) [37], and secondly, they possess "hyperactive" platelets, which are prone to forming thrombi. The rupture of an atherosclerotic plaque, combined with this augmented propensity for platelets to form large occlusive thrombi, increases the risk of fatal thrombotic events in diabetic individuals. Endothelial dysfunction, as well as the hyperactive phenotype of diabetic platelets, are well reported [38,39,40], but the exact underlying mechanisms remain largely unknown.

Alzheimer’s Disease

Diabetic patients also have an increased risk of developing Alzheimer's Disease (AD), a neurodegenerative disorder, although the exact relationship between these two diseases is poorly understood. Insulin signaling dysfunction has been reported in the AD brain, however, whether this is a cause or consequence of the disease has not yet been ascertained [41,42].

Cancer

There is growing evidence that abnormal insulin levels and dysregulated insulin signaling lead to cancer development and progression. A higher incidence of cancer is found in obese patients and those with type 2 diabetes. Many of the proteins that play a role in the insulin signaling pathways are involved in promoting cell proliferation and mitosis, as well as preventing apoptosis, which may increase the risk of tumor formation and metastasis [43].

Despite the tremendous progress made in understanding insulin and insulin receptor signaling over the last decades, there is still much left to be uncovered regarding how these complex networks regulate cells in both normal and disease states.

References

  1. James, D.E. et al. Insulin-regulatable Tissues Express a Unique Insulin-Sensitive Glucose Transport Protein. Nature. 1988.
  2. De Meyts, P. et al. The Insulin Receptor and Its Signal Transduction Network. Endotext. 2000.
  3. Ullrich, A. et al. Human Insulin Receptor and Its Relationship to the Tyrosine Kinase Family of Oncogenes. Nature. 1985.
  4. Ebina, Y. et al. The Human Insulin Receptor cDNA: The Structural Basis for Hormone-Activated Transmembrane Signalling. Cell. 1985.
  5. Sun, X.J. et al. Structure of the Insulin Receptor Substrate IRS-1 Defines a Unique Signal Transduction Protein. Nature. 1991.
  6. White, M.F. and Yenush, L. The IRS-signaling System: A Network of Docking Proteins That Mediate Insulin and Cytokine Action. Current Topics in Microbiology and Immunology. 1998.
  7. Ravichandran, K.S. Signaling via Shc Family Adapter Proteins. Oncogene. 2001.
  8. D'Alessandris, C. et al. C-reactive Protein Induces Phosphorylation of Insulin Receptor substrate-1 on Ser307 and Ser 612 in L6 Myocytes, Thereby Impairing the Insulin Signalling Pathway That Promotes Glucose Transport. Diabetologia. 2007.
  9. Shepherd, P.R. et al. The Role of Phosphoinositide 3-kinase in Insulin Signalling. Journal of Molecular Endocrinology. 1996.
  10. Shepherd, P.R. et al. Phosphoinositide 3-kinase: The Key Switch Mechanism in Insulin Signalling. The Biochemical Journal. 1998.
  11. Avruch, J. MAP Kinase Pathways: The First Twenty Years. Biochimica et Biophysica Acta. 2007.
  12. Cantley, L.C. The Phosphoinositide 3-kinase Pathway. Science. 2002.
  13. Taniguchi, C.M. et al. Critical Nodes in Signalling Pathways: Insights Into Insulin Action. Nature Reviews Molecular Cell Biology. 2006.
  14. Harris, T.E. and Lawrence, J.C. TOR Signaling. Science's Signal Transduction Knowledge Environment (STKE). 2003.
  15. Cohen, P. and Frame, S. The Renaissance of GSK3. Nature Reviews Molecular Cell Biology. 2001.
  16. Svendsen, AM. et al. Down-regulation of Cyclin G2 by Insulin, IGF-I (Insulin-Like Growth Factor 1) and X10 (AspB10 Insulin): Role in Mitogenesis. The Biochemical Journal. 2014
  17. Sano, H. et al. Insulin-stimulated Phosphorylation of a Rab GTPase-activating Protein Regulates GLUT4 Translocation. The Journal of Biological Chemistry.2003.
  18. Skolnik, EY. et al. The SH2/SH3 Domain-Containing Protein GRB2 Interacts With Tyrosine-Phosphorylated IRS1 and Shc: Implications for Insulin Control of Ras Signalling. The EMBO Journal. 1993.
  19. Gavin, G.R. et al. Insulin-dependent Regulation of Insulin Receptor Concentrations: A Direct Demonstration in Cell Culture. Proceedings of the National Academy of Sciences of the United States of America. 1974.
  20. Carpentier, J.L. Insulin Receptor Internalization: Molecular Mechanisms and Physiopathological Implications. Diabetologia. 1994.
  21. Hotamisligil, G.S. Mechanisms of TNF-alpha-induced Insulin Resistance. Exp Clin Endocrinol Diabetes. 1999.
  22. Elchebly, M. et al. Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine phosphatase-1B Gene. Science. 1999.
  23. Zhang, Z.Y. Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development. Annual Review of Pharmacology and Toxicology. 2002.
  24. Haj, F.G. et al. Imaging Sites of Receptor Dephosphorylation by PTP1B on the Surface of the Endoplasmic Reticulum. Science. 2002.
  25. Klaman, L.D. et al. Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-deficient Mice. Molecular and Cellular Biology. 2002.
  26. Brady, M.J. and Saltiel, A.R. The Role of Protein phosphatase-1 in Insulin Action. Recent Progress in Hormone Research. 2001.
  27. Millward, T.A. Regulation of Protein Kinase Cascades by Protein Phosphatase 2A. Trends in Biochemical Sciences. 1999.
  28. Kowluru, A. and Matti, A. Hyperactivation of Protein Phosphatase 2A in Models of Glucolipotoxicity and Diabetes: Potential Mechanisms and Functional Consequences. Biochemical Pharmacology. 2012.
  29. Ni, Y.G. et al. FoxO Transcription Factors Activate Akt and Attenuate Insulin Signaling in Heart by Inhibiting Protein Phosphatases. Proceedings of the National Academy of Sciences of the United States of America. 2007.
  30. Brognard, J. and Newton, A.C. PHLiPPing the Switch on Akt and Protein Kinase C Signaling. Trends in Endocrinology and Metabolism. 2007.
  31. Andreozzi, F. Increased Levels of the Akt-specific Phosphatase PH Domain Leucine-Rich Repeat Protein Phosphatase (PHLPP)-1 in Obese Participants Are Associated With Insulin Resistance. Diabetologia. 2011.
  32. Cozzone, D. et al. Isoform-specific Defects of Insulin Stimulation of Akt/protein Kinase B (PKB) in Skeletal Muscle Cells From Type 2 Diabetic Patients. Diabetologia. 2008.
  33. Maehama, T. and Dixon, J.E. PTEN: A Tumour Suppressor That Functions as a Phospholipid Phosphatase. Trends in Cell Biology. 1999.
  34. Emanuelli, B. et al. SOCS-3 Inhibits Insulin Signaling and Is Up-Regulated in Response to Tumor Necrosis Factor-Alpha in the Adipose Tissue of Obese Mice. The Journal of Biological Chemistry. 2001.
  35. Howard, J.K. and Flier, J.S. Attenuation of Leptin and Insulin Signaling by SOCS Proteins. Trends in Endocrinology and Metabolism. 2006.
  36. Qi, L. et al. Genetic Predisposition, Western Dietary Pattern, and the Risk of Type 2 Diabetes in Men. The American Journal of Clinical Nutrition. 2009.
  37. Gleissner, C.A. et al. Mechanisms by Which Diabetes Increases Cardiovascular Disease. Drug Discovery Today. Disease Mechanisms. 2007.
  38. Kaur, R. et al. Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies. Cardiovascular Diabetology. 2018.
  39. Li, Y. et al. Platelet Hyperactivity and Abnormal Ca(2+) Homeostasis in Diabetes Mellitus. American Journal of Physiology. Heart and Circulatory Physiology. 2001.
  40. Vinik, A.I. et al. Platelet Dysfunction in Type 2 Diabetes. Diabetes Care. 2001.
  41. Stanley, M. et al. Changes in Insulin and Insulin Signaling in Alzheimer's Disease: Cause or Consequence? The Journal of Experimental Medicine. 2016.
  42. Gabbouj, S. et al. Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. Frontiers in Neuroscience. 2019.
  43. Poloz, Y. and Stambolic, V. Obesity and Cancer, a Case for Insulin Signaling. Cell Death & Disease. 2015.
Menù Principale Contattaci 0Check-out
Inizio pagina